Featured Publications (Last 6 months)

1 Ryan NJ. Clinical Microbiology Procedures Handbook 4th ed ASM Parasitology (contributor)
2 Hanieh S, Ryan N, Biggs B-A. Assessing enteric helminths in refugees, asylum seekers and new migrants Australia Microbiology 37(1):15-19
3 Bruggink LD, Dunbar NL, Marshall JA. Emergence of GII.Pg norovirus in gastroenteritis outbreaks in Victoria, Australia Journal of Medical Virology; Epub
4 Thiem S, Eissmann MF, Elzer J, Jonas A, Putoczki TL, Poh A, Nguyen P, Preaudet A, Flanagan D, Vincan E, Waring P, Buchert M, Jarnicki A, Ernst M. Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model. Cancer Res. 76: 2277-87
5 Phesse T, Flanagan D, Vincan E. Frizzled7: A Promising Achilles’ Heel for Targeting the Wnt Receptor Complex to Treat Cancer Cancers (Basel).8(5). pii: E50
6 Roberts J, Thorley B, Bowden DS, Revill PA New Technologies for Viral Diagnosis and Detection. In White PA, Netzler, NE, Hansman GS. (ed), Foodborne Viral Pathogens.
7 Visvanathan K, Dusheiko G, Giles M, Wong ML, Phung N, Walker S, Le S, Lim SG, Gane E, Ngu M, Hardikar W, Cowie B, Bowden S, Strasser S, Levy M, Sasaduesz J Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders. Gut 65: 340-360.
8 Audsley J, Bent SJ, Littlejohn M, Avihingsanon A, Matthews G, Bowden S, Bayliss J, Luciani F, Yuen L, Fairley C, Locarnini S, Lewin S, Sasadeusz J. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity. AIDS 30: 1597-1606.
9 Locarnini S, Chen DS, Shibuya K. No more excuses: viral hepatitis can be eliminated. Lancet. 23;387(10029):1703-4.
10 Revill P, Testoni B, Locarnini S, Zoulim F. Global strategies are required to cure and eliminate HBV infection. Nat Rev Gastroenterol Hepatol;13(4):239-48.
11 Revill PA, Locarnini SA. New perspectives on the hepatitis B virus life cycle in the human liver. J Clin Invest. 2016 Mar 1;126(3):833-6.
12 Littlejohn M, Locarnini S, Yuen L. Origins and Evolution of Hepatitis B Virus and Hepatitis D Virus. Cold Spring Harb Perspect Med. 2016 Jan 4;6(1):a021360.
13 S. K. Sarin, M. Kumar, G. K. Lau, Z. Abbas, H. L. Y. Chan, C. J. Chen, D. S. Chen, H. L. Chen, P. J. Chen, R. N. Chien, A. K. Dokmeci, Ed Gane, J. L. Hou, W. Jafri, J. Jia, J. H. Kim, C. L. Lai, H. C. Lee, S. G. Lim, C. J. Liu, S. Locarnini, M. Al Mahtab, R. Mohamed, M. Omata, J. Park, T. Piratvisuth, B. C. Sharma, J. Sollano, F. S. Wang, L. Wei, M. F. Yuen, S. S. Zheng, and J. H. Kao Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1-98.
14 Visvanathan K, Lang T, Ryan K, Wilson R, Skinner NA, Thompson AJ, Ahn SH, Weilert F, Abbott W, Gane E, Colledge D, Li K, Locarnini S, Mansell A, Revill PA. Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients. J Viral Hepat. 2016 Mar;23(3):170-9
15 Wallace J, Pitts M, Locarnini S, Ellard J, Carman M, Chen DS. Essential components in developing public policy to control viral hepatitis: lessons from Taiwan. Hepatol Int. 2016 Mar;10(2):355-62.
16 Rybczynska J, Campbell K, Kamili S, Locarnini S, Krawczynski K, Walker CM. CD4+ T Cells Are Not Required for Suppression of Hepatitis B Virus Replication in the Liver of Vaccinated Chimpanzees. J Infect Dis. 2016 Jan 1;213(1):49-56.
17 Globan M, Lavender C, Leslie D, Brown L, Denholm J, Raios K, Sievers A, Kelly H, Fyfe J Molecular epidemiology of tuberculosis in Victoria, Australia, reveals low level of transmission Int J Tuberc Lung Dis
18 Vanderven HA, Ana-Sosa-Batiz F, Jegaskanda S, Rockman S, Laurie K, Barr I, Chen W, Wines B, Hogarth PM, Lambe T, Gilbert SC, Parsons MS, Kent SJ. What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. EBioMedicine. 2016 Jun;8:277-90
19 Ana-Sosa-Batiz F, Vanderven H, Jegaskanda S, Johnston A, Rockman S, Laurie K, Barr I, Reading P, Lichtfuss M, Kent SJ. Influenza-Specific Antibody-Dependent Phagocytosis. PLoS One. 2016 Apr 28;11(4):e0154461
20 Barr IG, Vijaykrishna D, Sullivan SG. Differential age susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian influenza season. Euro Surveill. ;21(4).
21 Kotecha RS, Wadia UD, Jacoby P, Ryan AL, Blyth CC, Keil AD, Gottardo NG, Cole CH, Barr IG, Richmond PC. Immunogenicity and clinical effectiveness of the trivalent inactivated influenza vaccine in immunocompromised children undergoing treatment for cancer. Cancer Med. 5(2): 285–293
22 Milne GJ, Halder N, Kelso JK, Barr IG, Moyes J, Kahn K, Twine R, Cohen C. Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study. Influenza Other Respir Viruses. ;10(4):324-32
23 Ren B, McKinstry WJ, Pham T, Newman J, Layton DS, Bean AG, Chen Z, Laurie KL, Borg K, Barr IG, Adams TE. Structural and functional characterisation of ferret interleukin-2. Dev Comp Immunol;55:32
24 Hurt AC, Besselaar TG, Daniels RS, Ermetal B, Fry A, Gubareva L, Huang W, Lackenby A, Lee RT, Lo J, Maurer-Stroh S, Nguyen HT, Pereyaslov D, Rebelo-de-Andrade H, Siqueira MM, Takashita E, Tashiro M, Tilmanis D, Wang D, Zhang W, Meijer A. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015. Antiviral Res. 132:178-185
25 Hurt AC, Kelly H. Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza. Emerg Infect Dis, (6):949-55
26 Dalziel AE, Peck HA, Hurt AC, Cooke J, Cassey P Proposed Surveillance for Influenza A in Feral Pigs. Ecohealth 12; pg 1-5
27 Oh DY, Hurt AC. Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness. Front Microbiol;7:80.
28 Gillespie L, Gerstenberg K, Ana-Sosa-Batiz F, Parsons MS, Farrukee R, Krabbe M, Spann K, Brooks AG, Londrigan SL, Reading PC. DC-SIGN and L-SIGN are attachment factors that promote infection of target cells by human metapneumovirus in the presence or absence of cellular glycosaminoglycans. J Virol.;90(17):7848-63.
29 Job ER, Pizzolla A, Nebl T, Short KR, Deng YM, Carolan L, Laurie KL, Brooks AG, Reading PC. Neutralizing inhibitors in the airways of naïve ferrets do not play a major role in modulating the virulence of H3 subtype influenza A viruses. Virology. 494:143-57
30 FitzPatrick M, Royce SG, Langenbach S, McQualter J, Reading PC, Wijburg O, Anderson GP, Stewart A, Bourke J, Bozinovski S. Neonatal pneumococcal colonisation caused by Influenza A infection alters lung function in adult mice. Sci Rep;6:22751.
31 Stowe J, Andrews N, Kosky C, Dennis G, Eriksson S, Hall A, Leschziner G, Reading P, Shneerson JM, Donegan K, Miller E. Risk of Narcolepsy after AS03 Adjuvanted Pandemic A/H1N1 2009 Influenza Vaccine in Adults: A Case-Coverage Study in England. Sleep.;39(5):1051-7
32 Gillespie L, Roosendahl P, Ng WC, Brooks AG, Reading PC, Londrigan SL. Endocytic function is critical for influenza A virus infection via DC-SIGN and L-SIGN. Sci Rep;6:19428
33 Kristensen AB, Lay WN, Ana-Sosa-Batiz F, Vanderven HA, Madhavi V, Laurie KL, Carolan L, Wines BD, Hogarth M, Wheatley AK, Kent SJ Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine. J Virol;90(12):5724-34
34 Eichelberger MC, Couzens L, Gao Y, Levine M, Katz J, Wagner R, Thompson CI, Höschler K, Laurie K, Bai T, Engelhardt OG; ELLA study participants, Wood J. Comparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicity. Vaccine; 34, (4): 458–465
35 Ren B, McKinstry WJ, Pham T, Newman J, Layton DS, Bean AG, Chen Z, Laurie KL, Borg K, Barr IG, Adams TE. Structural and functional characterisation of ferret interleukin-2. Dev Comp Immunol;55:32-8.
36 Leung VK, Cowling BJ, Feng S, Sullivan SG. Concordance of interim and final estimates of influenza vaccine effectiveness: a systematic review. Euro Surveill;21(16)
37 Feng S, Cowling BJ, Sullivan SG. Influenza vaccine effectiveness by test-negative design – Comparison of inpatient and outpatient settings. Vaccine;34(14):1672-9
38 Fielding JE, Regan AK, Dalton CB, Chilver MB, Sullivan SG. How severe was the 2015 influenza season in Australia? Med J Aust. ;204(2):60-1
39 Bond HS, Sullivan SG, Cowling BJ. Regression approaches in the test-negative study design for assessment of influenza vaccine effectiveness. Epidemiol Infect.144(8):1601-11
40 Komadina N, Quinones-Parra SM, Kedzierska K, McCaw JM, Kelso A, Leder K, et al. High conservation level of CD8 T cell immunogenic regions within an unusual H1N2 human influenza variant. J Med Virol. ;88(10):1725-32
41 Sullivan SG, Carville K, Chilver M, Grant K, Kelly H, Levy A, Stocks N, Tempone S, Regan Pooled inuenza vaccine effectiveness estimates for Australia, 2012-2014 Epidemiol Infect.;144:2317-28